Biolegend, 101342, Ultra-LEAF™ Purified anti-mouse CD16/32 Antibody, 100mg

CD16 is low affinity IgG Fc receptor III (FcR III) and CD32 is FcR II. CD16/CD32 are expressed on B cells, monocytes/macrophages, NK cells, granulocytes, mast cells, and dendritic cells. The Fc receptors bind antibody-antigen immune complexes and mediate adaptive immune responses.
100mg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Sorted pre-B cells
Formulation: 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level: Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.
Preparation: The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration: The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application: FC - Quality tested IP, Block - Reported in the literature, not verified in house
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per million cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: Clone 93 can be used for blocking of CD16/CD32 interactions with the Fc domain of immunoglobulins, but is not the same clone as 2.4G2.The 93 mAb is specific to the common epitope of CD16/CD32. Additional reported applications (for the relevant formats) include: immunoprecipitation1 and blocking of Fc-mediated reactions in functional studies2,4,23. It is useful for blocking non-specific binding of immunoglobulin to Fc receptors. For blocking of Fc receptors in flow cytometric analysis, pre-incubate the cells with purified anti-CD16/CD32 antibody (=1.0 µg per 106 cells in 100 µL volume) for 5-10 minutes on ice prior to immunostaining. For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 101330) (Endotoxin <0.01 EU/µg, Azide-Free, 0.2 µm filtered).
Application References(PubMed link indicates BioLegend citation): Personal communication (IP) Oliver AM, et al. 1999. Hybridoma 18:113. (Block) Brummel R and Lenert P. 2005. J. Immunol. 174:2429. Terrazas LI, et al. 2005. Int. J. Parasitol. 35:1349. (Block) Clements JL, et al. 2006. J. Immunol. 177:905. Mohamed W, et al. 2010. Infect Immun. 78:3306. PubMed Ouchi T, et al. 2011. J. Exp Med. 208:2607. PubMed Kmieciak M, et al. 2011. J. Vis. Exp. 47:2381. PubMed Yamazaki S, et al. 2012. PLoS One. 7:e51665. PubMed Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed Azuma M, et al. 2012. Oncoimmunology. 1:581. PubMed Koon HW, et al. 2013. J. Vis. Exp. 68:4208. PubMed Hegde VL, et al. 2013. J Biol Chem. 288:36810. PubMed Huang J, et al. 2013. J. Immunol Methods. 387:254. PubMed Dutow P, et al. 2014. J Infect Dis. PubMed Fan Y, et al. 2014. J Exp Med. 211:313. PubMed Huang HN, et al. 2014. Antimicrob Agents Chemother. 58:1538. PubMed Takei S, et al. 2014. Vaccine. 32:3066. PubMed Richardson ML, et al. 2014. PLoS Negl Trop Dis. 8:2825. PubMed Cekanaviciute E, et al. 2014. J Immunol. 193:139. PubMed Kimura T, et al. 2014. Int Immunol. 26:697. PubMed Everad A, et al. 2014. Nat Commun. 5:5648. PubMed Cenci E, et al. 2006. J. Leuko. Biol. 79(1):40-5. (Block)
Product Citations: Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed van Os BW, et al. 2023. Eur Heart J Open. 3:oead013. PubMed van Os BW, et al. 2023. Front Cardiovasc Med. 10:1171764. PubMed Matsudaira T, et al. 2023. Commun Biol. 6:665. PubMed Liang Y, et al. 2021. Cell Death Differ. 28:2728. PubMed Miranda K, et al. 2022. iScience. 25:104994. PubMed Kraemer AN, et al. 2022. Front Immunol. 13:933191. PubMed Yang L, et al. 2023. Sci Rep. 13:1827. PubMed Nair N, et al. 2020. Curr Protoc Microbiol. 59:e127. PubMed Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed Petursdottir D, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01699. PubMed Xie Y, et al. 2020. Journal of Neurochemistry. 152(3):368-380.. PubMed Lercher A, et al. 2019. Immunity. 51:1074. PubMed Pfenninger P, et al. 2022. Front Immunol. 13:777113. PubMed Guérin MV, et al. 2019. Nat Commun. 10:4131. PubMed Guo P, et al. 2021. J Immunol. 207:408. PubMed Li D, et al. 2022. Emerg Microbes Infect. 11:2248. PubMed Arensman MD, et al. 2020. Oncoimmunology. 9:1800162. PubMed Le TM et al. 2018. Journal of neurochemistry. 145(2):139-153 . PubMed Fox A, et al. 2020. Current Protocols in Cytometry. 93(1):e74. PubMed Schäfer AL, et al. 2021. Front Immunol. 12:696810. PubMed Tong Y, et al. 2018. EBioMedicine. 39:132. PubMed Trindade BC, et al. 2021. Immunity. 54:2273. PubMed Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
RRID: AB_2783037 (BioLegend Cat. No. 101329) AB_2561482 (BioLegend Cat. No. 101330) AB_2616683 (BioLegend Cat. No. 101339) AB_2616684 (BioLegend Cat. No. 101340) AB_2783038 (BioLegend Cat. No. 101341) AB_2783039 (BioLegend Cat. No. 101342)
Structure: Ig superfamily, 40-60 kD
Distribution: B cells, monocyte/macrophages, NK cells, neutrophils, mast cells, dendritic cells
Function: Low affinity receptors for IgG
Ligand/Receptor: IgG
Cell Type: B cells, Dendritic cells, Macrophages, Mast cells, Monocytes, Neutrophils, NK cells
Biology Area: Immunology, Innate Immunity
Molecular Family: CD Molecules, Fc Receptors
Antigen References: 1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Unkeless JC. 1989. J. Clin. Invest. 83:355. 3. Qiu WQ, et al. 1990. Science 248:732.
Gene ID: 1413014131
UniProt: View information about CD16/32 on UniProt.org
Clone: 93
Regulatory Status: RUO
Other Names: Fcγ R III/II, Ly-17
Isotype: Rat IgG2a, λ
Q: Do you guarantee that your antibodies are totally pathogen free?
A: BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.
Q: Does BioLegend test each Ultra-LEAF™ antibody by functional assay?
A: No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.
Q: Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?
A: No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.
Q: Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?
A: We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.